News
- Author:
- Patrice Wendling
Publish date: July 10, 2014
Key clinical point: Combination olaparib plus cediranib may provide an alternative treatment option for women with recurrent, platinum-sensitive o...
News
- Author:
- Patrice Wendling
Publish date: July 10, 2014
Key clinical point: PEI chemotherapy improves survival in sensitive relapsed SCLC, but at a cost of greater toxicity.Major finding: Median overall...
News
- Author:
- Patrice Wendling
Publish date: July 10, 2014
Key clinical point: An antimetabolite strategy that cuts off the supply of arginine to tumors may benefit patients with mesothelioma.Major finding...
News
- Author:
- Patrice Wendling
Publish date: July 9, 2014
Key clinical point: Adjuvant EGFR TKI therapy may prolong disease progression in NSCLC patients harboring an EGFR mutation.Major finding: Median D...
News
- Author:
- Patrice Wendling
Publish date: July 9, 2014
Key clinical point: Thoracic radiotherapy may improve survival when delivered after chemotherapy in extensive-stage lung cancer responding to chem...
News
- Author:
- Patrice Wendling
Publish date: July 7, 2014
Major finding: In the sample, 62% of high-volume hospitals achieved high patient satisfaction, vs. 38% of low-volume hospitals.
News
- Author:
- Patrice Wendling
Publish date: July 7, 2014
Major finding: The 5-year FFTF rate was 93.1% with ABVD and 89.2% with AVD (HR, 1.50; 95% confidence interval, 1.00-2.26).Data source: A prospecti...
News
- Author:
- Patrice Wendling
Publish date: July 7, 2014
Major finding: The 5-year FFTF rate was 93.1% with ABVD and 89.2% with AVD (HR, 1.50; 95% confidence interval, 1.00-2.26).Data source: A prospecti...
News
- Author:
- Patrice Wendling
Publish date: June 27, 2014
Key clinical point: Elderly patients with newly diagnosed AML benefit from first-line azacitidine.Major finding: Median overall survival was 10.4 ...
News
- Author:
- Patrice Wendling
Publish date: June 27, 2014
Major finding: The skeletal-related event rate was 23.2% with zoledronic acid every 12 weeks and 22% with zoledronic acid every 4 weeks (P = .724)...
News
- Author:
- Patrice Wendling
Publish date: June 26, 2014
Key clinical point: Exemestane plus OFS is a new treatment option in the setting of premenopausal hormone-sensitive early breast cancer.Major find...
News
- Author:
- Patrice Wendling
Publish date: June 26, 2014
Major finding: Any grade 3/4 toxicity was reported in 36.6% of patients and grade 3/4 hematologic toxicity, in 9.8%.Data source: A phase II study ...
News
- Author:
- Patrice Wendling
Publish date: June 24, 2014
Key clinical point: AG-221 could shift the treatment for IDH2 mutation-positive hematologic cancers.
Major finding: Fourteen of 25 patients respon...
News
- Author:
- Patrice Wendling
Publish date: June 23, 2014
Major finding: Idelalisib and rituximab significantly increased progression-free survival (HR, 0.18; P less than .0001).
Data source: A prospectiv...
News
- Author:
- Patrice Wendling
Publish date: June 20, 2014
Key clinical point: Palliative care delivered at the time of cancer diagnosis improves survival.Major finding: The risk of death at 1 year was sig...
